Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)

Market Cap	8.31B -42.2%
Revenue (ttm)	36.45M +13.8%
Net Income	-114.13M
EPS	-0.92
Shares Out	122.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	264,905
Average Volume	278,934
Open	69.50
Previous Close	69.10
Day's Range	66.90 - 70.00
52-Week Range	67.20 - 118.00
Beta	-0.03
RSI	32.27
Earnings Date	May 12, 2026

About Gongwin Biopharm Holdings

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6617

Financial Performance

In 2025, Gongwin Biopharm Holdings's revenue was 36.45 million, an increase of 13.75% compared to the previous year's 32.04 million. Losses were -114.13 million, 38.3% more than in 2024.